NOXO.F Stock Overview
A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Noxopharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.045 |
| 52 Week High | AU$0.045 |
| 52 Week Low | AU$0.03 |
| Beta | 0.78 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -92.50% |
| 5 Year Change | n/a |
| Change since IPO | -76.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOXO.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how NOXO.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how NOXO.F performed against the US Market.
Price Volatility
| NOXO.F volatility | |
|---|---|
| NOXO.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NOXO.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NOXO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Gisela Mautner | www.noxopharm.com |
Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types.
Noxopharm Limited Fundamentals Summary
| NOXO.F fundamental statistics | |
|---|---|
| Market cap | US$14.62m |
| Earnings (TTM) | -US$7.98m |
| Revenue (TTM) | US$2.55m |
5.8x
P/S Ratio-1.9x
P/E RatioIs NOXO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOXO.F income statement (TTM) | |
|---|---|
| Revenue | AU$3.88m |
| Cost of Revenue | AU$6.30m |
| Gross Profit | -AU$2.43m |
| Other Expenses | AU$9.70m |
| Earnings | -AU$12.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | -62.60% |
| Net Profit Margin | -312.86% |
| Debt/Equity Ratio | 0% |
How did NOXO.F perform over the long term?
See historical performance and comparison